US Patent Issued to TRANSLATE BIO on Jan. 27 for "MRNA therapy for argininosuccinate synthetase deficiency" (Massachusetts Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,533,402, issued on Jan. 27, was assigned to TRANSLATE BIO INC. (Waltham, Mass.).

"MRNA therapy for argininosuccinate synthetase deficiency" was invented by Michael Heartlein (Lexington, Mass.), Frank DeRosa (Lexington, Mass.) and Lianne Boeglin (Lexington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides, among other things, methods of treating Argininosuccinate Synthetase Deficiency (ASD), including administering to a subject in need of treatment a composition comprising an mRNA encoding argininosuccinate synthetase (ASS1) at an effective dose and an administration interval such that at least one symptom or feature of...